Skip to main content
Premium Trial:

Request an Annual Quote

Seiko Epson, Stanford University, Oncotech, Affymetrix, CombiMatrix, Enzo Life Sciences, Agilent Technologies

Premium
Seiko Epson of Tokyo has received US Patent no. 7,323,224, “Liquid dispense method and microarray manufacturing method.” The patent claims a method for discharging a liquid containing a biological material onto a substrate. The method includes adding as a dispense stabilizer a polymer composed of phosphorylcholine-group-containing unsaturated compound units or a copolymer including same to the liquid containing the biological material and discharging the liquid containing the dispense stabilizer using an inkjet system.
 

 
Stanford University of Palo Alto, Calif., has received US Patent No. 7,323,298, “Microarray for determining the relative abundances of polynuceotide sequences.” The patent claims a method of determining the relative amounts of individual polynucleotides in a complex mixture of different-sequence polynucleotides. The polynucleotides, after fluorescent labeling, are first contacted under hybridization conditions with an array of different DNA sequences disposed at discrete locations on a non-porous surface, where the different DNA sequences in the array are effective to hybridize to individual polynucleotides in the mixture. The level of fluorescence associated with each array sequence can then provide a measure of its relative amount in the mixture, according to the patent.
 

 
Oncotech of Tustin, Calif., has received US Patent No. 7,323,300, “Methods for cancer prognosis and diagnosis.” The patent claims a method for detecting a gene expression profile of living neoplastic cells that are resistant to a cytotoxic compound using a microarray and distinguishing the profile from the gene expression profile of living neoplastic cells that are sensitive to the cytotoxic compound in a mixed population of cells from a tumor sample.
 

 
Affymetrix has received US Patent No. 7,323,307, “Identification of molecular sequence signatures and methods involving the same.” The patent claims methods for analyzing hybridization data derived from hybridization assays between a target nucleic acid and differently sequenced polynucleotide probes. The method is useful for determining whether the target contains a nucleic acid or polypeptide sequence signature, whether the target encodes a member of a gene family, or whether the target is derived from one of any number of genes, according to the patent’s abstract.
 

 
CombiMatrix of Mulkiteo, Wash., has received US Patent No. 7,323,320, “Microarray synthesis and assembly of gene-length polynucleotides.” The patent claims a process for in vitro synthesis and assembly of long, gene-length polynucleotides based upon assembly of multiple shorter oligonucleotides synthesized in situ on a microarray platform. Specifically, there a process is described for in situ synthesis of oligonucleotide fragments on a solid phase microarray platform and subsequent, ‘on device’ assembly of larger polynucleotides composed of a plurality of shorter oligonucleotide fragments.
 

 
Enzo Life Sciences of Farmingdale, NY, has received US Patent No. 7,323,571, “Heterodimeric dye composition.” The patent describes labeling reagents, labeled targets, and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes, and are useful for labeling probes or targets including nucleic acids and proteins. The reagents can also be usefully applied to protein and nucleic acid probe based assays and are applicable to real-time detection processes.
 

 
Agilent Technologies has received US Patent No. 7,324,677, “Feature quantitation methods and system.” The patent claims methods, systems and recordable media for reading and identifying high-quality signals from a microarray feature. According to the patent, signals may be identified and used regardless of their geographic or geometric locations and patterns within the feature zone. High-quality signals may be read, identified, and outputted from a microarray feature in a geometrically independent manner, so that the best quality signals are identified and useable, regardless of the locations or patterns in the region from which the best quality signals are outputted.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.